{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:24:12Z","timestamp":1784175852036,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Project of the Nantong Health Committee","award":["QNZ2023058"],"award-info":[{"award-number":["QNZ2023058"]}]},{"name":"Nantong Science and Technology Bureau Project","award":["MSZ2024089"],"award-info":[{"award-number":["MSZ2024089"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03781-9","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:24:25Z","timestamp":1761042265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling the global research status and intellectual map of cancer and immunosuppressants"],"prefix":"10.1007","volume":"16","author":[{"given":"Tianyi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunna","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"3781_CR1","doi-asserted-by":"publisher","unstructured":"Zhou J et al. Aggregation-Induced Emission Luminogens for Enhanced Photodynamic Therapy: From Organelle Targeting to Tumor Targeting, (in eng), Biosensors (Basel), vol. 12, no. 11, Nov 16 2022, https:\/\/doi.org\/10.3390\/bios12111027","DOI":"10.3390\/bios12111027"},{"key":"3781_CR2","doi-asserted-by":"publisher","unstructured":"D\u00f6kmeta\u015f M et al. Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis, (in eng), Medicina (Kaunas), vol. 61, no. 1, Jan 14 2025, https:\/\/doi.org\/10.3390\/medicina61010123","DOI":"10.3390\/medicina61010123"},{"key":"3781_CR3","doi-asserted-by":"publisher","unstructured":"Giussani P, Prinetti A, Tringali C. The role of sphingolipids in cancer Immunotherapy, (in eng). Int J Mol Sci. Jun 17 2021;22(12). https:\/\/doi.org\/10.3390\/ijms22126492.","DOI":"10.3390\/ijms22126492"},{"key":"3781_CR4","doi-asserted-by":"publisher","unstructured":"Liu WN et al. Successful targeting of PD-1\/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model, (in eng), Sci Adv, vol. 8, no. 47, p. eadd1187, Nov 25 2022, https:\/\/doi.org\/10.1126\/sciadv.add1187","DOI":"10.1126\/sciadv.add1187"},{"issue":"11","key":"3781_CR5","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.62347\/mjoa5699","volume":"16","author":"H Zhang","year":"2024","unstructured":"Zhang H, Jiang Y, Luo J, Tan Q, Xu M, He B. Predictive and prognostic value of combined detection of sTim-3, PG and PD-L1 in immune checkpoint inhibitor therapy for advanced gastric cancer, (in eng). Am J Transl Res. 2024;16(11):6955\u201363. https:\/\/doi.org\/10.62347\/mjoa5699.","journal-title":"Am J Transl Res"},{"key":"3781_CR6","doi-asserted-by":"publisher","first-page":"1499478","DOI":"10.3389\/fimmu.2024.1499478","volume":"15","author":"J Strouse","year":"2024","unstructured":"Strouse J, et al. Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis. Front Immunol. 2024;15:1499478. https:\/\/doi.org\/10.3389\/fimmu.2024.1499478. (in eng).","journal-title":"Front Immunol"},{"key":"3781_CR7","doi-asserted-by":"publisher","unstructured":"Jiacheng D, Jiayue C, Ying G, Shaohua W, Wenhui L, Xinyu H. Research progress and challenges of the PD-1\/PD-L1 axis in gliomas, (in eng). Cell Biosci. Sep 27 2024;14(1):123. https:\/\/doi.org\/10.1186\/s13578-024-01305-6.","DOI":"10.1186\/s13578-024-01305-6"},{"key":"3781_CR8","doi-asserted-by":"publisher","unstructured":"Elhelbawy NG, Nassar AAH, Eltorgoman AEA, Saber SM, Badr EA. Immunological microenvironment gene expression in patients with diffuse large B cell Non hodgkin lymphoma, (in eng). Biochem Biophys Rep. Mar 2020;21:100731. https:\/\/doi.org\/10.1016\/j.bbrep.2020.100731.","DOI":"10.1016\/j.bbrep.2020.100731"},{"key":"3781_CR9","doi-asserted-by":"publisher","unstructured":"Liu Y et al. A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice, (in eng), Nat Commun, vol. 16, no. 1, p. 2854, Mar 24 2025, https:\/\/doi.org\/10.1038\/s41467-025-57965-6","DOI":"10.1038\/s41467-025-57965-6"},{"key":"3781_CR10","doi-asserted-by":"publisher","unstructured":"Xu K et al. Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis, (in eng), Ann Med, vol. 57, no. 1, p. 2482019, Dec 2025, https:\/\/doi.org\/10.1080\/07853890.2025.2482019","DOI":"10.1080\/07853890.2025.2482019"},{"key":"3781_CR11","doi-asserted-by":"publisher","unstructured":"Chen H, Xu Y, Liu J, Yang S, Jiang H, Chen Z. Analysis of the association between immune-related adverse events and the effectiveness in patients with advanced non-small-cell-lung cancer, (in eng). Discov Oncol. Oct 8 2024;15(1):534. https:\/\/doi.org\/10.1007\/s12672-024-01413-2.","DOI":"10.1007\/s12672-024-01413-2"},{"key":"3781_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2020.10.004","volume":"160","author":"MP Manspeaker","year":"2020","unstructured":"Manspeaker MP, Thomas SN. Lymphatic Immunomodulation using engineered drug delivery systems for cancer immunotherapy, (in eng). Adv Drug Deliv Rev. 2020;160:19\u201335. https:\/\/doi.org\/10.1016\/j.addr.2020.10.004.","journal-title":"Adv Drug Deliv Rev"},{"key":"3781_CR13","doi-asserted-by":"publisher","unstructured":"Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: How great is the impact? (in eng), Scientometrics, vol. 105, no. 3, pp. 1809\u20131831, 2015, https:\/\/doi.org\/10.1007\/s11192-015-1645-z","DOI":"10.1007\/s11192-015-1645-z"},{"key":"3781_CR14","doi-asserted-by":"publisher","unstructured":"Engels EA et al. Spectrum of cancer risk among US solid organ transplant recipients, (in eng), Jama, vol. 306, no. 17, pp. 1891\u2009\u2013\u2009901, Nov 2 2011, https:\/\/doi.org\/10.1001\/jama.2011.1592","DOI":"10.1001\/jama.2011.1592"},{"key":"3781_CR15","doi-asserted-by":"publisher","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, (in eng), N Engl J Med, vol. 378, no. 2, pp. 158\u2013168, Jan 11 2018, https:\/\/doi.org\/10.1056\/NEJMra1703481","DOI":"10.1056\/NEJMra1703481"},{"key":"3781_CR16","doi-asserted-by":"publisher","unstructured":"Brahmer JR, et al. Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice Guideline, (in eng). J Clin Oncol. Jun 10 2018;36:1714\u201368. https:\/\/doi.org\/10.1200\/jco.2017.77.6385.","DOI":"10.1200\/jco.2017.77.6385"},{"key":"3781_CR17","doi-asserted-by":"publisher","unstructured":"Beaugerie L et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, (in eng), Lancet, vol. 374, no. 9701, pp. 1617-25, Nov 7 2009, https:\/\/doi.org\/10.1016\/s0140-6736(09)61302-7","DOI":"10.1016\/s0140-6736(09)61302-7"},{"key":"3781_CR18","doi-asserted-by":"publisher","unstructured":"Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma, (in eng), N Engl J Med, vol. 363, no. 8, pp. 711\u2009\u2013\u200923, Aug 19 2010, https:\/\/doi.org\/10.1056\/NEJMoa1003466","DOI":"10.1056\/NEJMoa1003466"},{"key":"3781_CR19","doi-asserted-by":"publisher","unstructured":"Colombel JF, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease, (in eng). N Engl J Med. Apr 15 2010;362:1383\u201395. https:\/\/doi.org\/10.1056\/NEJMoa0904492.","DOI":"10.1056\/NEJMoa0904492"},{"key":"3781_CR20","doi-asserted-by":"publisher","unstructured":"Larkin J et al. Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma, (in eng). N Engl J Med, 373, 1, pp. 23\u201334, Jul 2 2015, https:\/\/doi.org\/10.1056\/NEJMoa1504030","DOI":"10.1056\/NEJMoa1504030"},{"key":"3781_CR21","doi-asserted-by":"publisher","unstructured":"Verhaert MAM, Aspeslagh S. Immunotherapy efficacy and toxicity: reviewing the evidence behind patient implementable strategies, (in eng). Eur J Cancer. Sep 2024;209:114235. https:\/\/doi.org\/10.1016\/j.ejca.2024.114235.","DOI":"10.1016\/j.ejca.2024.114235"},{"key":"3781_CR22","doi-asserted-by":"publisher","unstructured":"von Itzstein MS, Gerber DE, Bermas BL, Meara A. Acknowledging and addressing real-world challenges to treating immune-related adverse events, (in eng). J Immunother Cancer. Jul 22 2024;12(7). https:\/\/doi.org\/10.1136\/jitc-2024-009540.","DOI":"10.1136\/jitc-2024-009540"},{"key":"3781_CR23","doi-asserted-by":"publisher","unstructured":"Machado AP et al. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review, (in eng), J Cancer, vol. 14, no. 16, pp. 2956\u20132963, 2023, https:\/\/doi.org\/10.7150\/jca.87335","DOI":"10.7150\/jca.87335"},{"key":"3781_CR24","unstructured":"Hashash JG, Francis FF, Farraye FA. Diagnosis and management of immune checkpoint inhibitor colitis. Gastroenterol Hepatol (N Y), 17, 8, pp. 358\u201366, 2021\/8\/\/."},{"key":"3781_CR25","doi-asserted-by":"crossref","unstructured":"Haanen J et al. Management of toxicities from immunotherapy: ESMO clinical practice Gu ideline for diagnosis, treatment and follow-up. Ann Oncol, 33, 12, pp. 1217\u201338, doi: 10.1016\/j.annonc.2022.10.001.","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"3781_CR26","doi-asserted-by":"publisher","unstructured":"Matsukane R, et al. Krebs von Den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis, (in eng). J Immunother Cancer. Dec 22 2024;12(12). https:\/\/doi.org\/10.1136\/jitc-2024-010114.","DOI":"10.1136\/jitc-2024-010114"},{"key":"3781_CR27","doi-asserted-by":"publisher","first-page":"994064","DOI":"10.3389\/fimmu.2022.994064","volume":"13","author":"KC Lai","year":"2022","unstructured":"Lai KC, Hsiao YH, Chen SC. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: case report and review, (in eng). Front Immunol. 2022;13:994064. https:\/\/doi.org\/10.3389\/fimmu.2022.994064.","journal-title":"Front Immunol"},{"key":"3781_CR28","doi-asserted-by":"publisher","unstructured":"Ertl C, et al. Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: interim analysis of a prospective two-arm study, (in eng). Eur J Cancer. Nov 2024;212:115049. https:\/\/doi.org\/10.1016\/j.ejca.2024.115049.","DOI":"10.1016\/j.ejca.2024.115049"},{"key":"3781_CR29","doi-asserted-by":"publisher","unstructured":"Chen Y, Luo Y, Liu Y, Luo D, Liu A. Dual efficacy of Tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study, (in eng). Cancer Immunol Immunother. Jan 3 2025;74(2):52. https:\/\/doi.org\/10.1007\/s00262-024-03899-9.","DOI":"10.1007\/s00262-024-03899-9"},{"key":"3781_CR30","doi-asserted-by":"publisher","unstructured":"Petit PF, et al. Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study, (in eng). Ann Oncol. Jan 2025;36(1):43\u201353. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2340.","DOI":"10.1016\/j.annonc.2024.08.2340"},{"key":"3781_CR31","doi-asserted-by":"publisher","unstructured":"Maloney AK, et al. Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab, (in eng). J Immunother Cancer. Aug 28 2024;12(8). https:\/\/doi.org\/10.1136\/jitc-2024-009061.","DOI":"10.1136\/jitc-2024-009061"},{"key":"3781_CR32","doi-asserted-by":"publisher","unstructured":"van Not OJ et al. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma, (in eng), JAMA Oncol, vol. 8, no. 12, pp. 1794\u20131801, Dec 1., 2022, https:\/\/doi.org\/10.1001\/jamaoncol.2022.5041","DOI":"10.1001\/jamaoncol.2022.5041"},{"key":"3781_CR33","doi-asserted-by":"publisher","unstructured":"Brown LJ, et al. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders, (in eng). J Immunother Cancer. May 2021;9(5). https:\/\/doi.org\/10.1136\/jitc-2020-002121.","DOI":"10.1136\/jitc-2020-002121"},{"key":"3781_CR34","doi-asserted-by":"publisher","unstructured":"Horvat TZ, et al. Immune-Related adverse Events, need for systemic Immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer Center, (in eng). J Clin Oncol. Oct 1 2015;33(28):3193\u20138. https:\/\/doi.org\/10.1200\/jco.2015.60.8448.","DOI":"10.1200\/jco.2015.60.8448"},{"key":"3781_CR35","doi-asserted-by":"publisher","unstructured":"Kramer R, et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors, (in eng). Eur J Cancer. Apr 2021;147:170\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.013.","DOI":"10.1016\/j.ejca.2021.01.013"},{"key":"3781_CR36","doi-asserted-by":"crossref","unstructured":"Petrelli F, Morelli AM, Luciani A, Ghidini A, Solinas C. Risk of infection with immune checkpoint inhibitors: A systematic revi Ew and Meta-analysis. Target Oncol, 16, 5, pp. 553\u201368, doi: 10.1007\/s11523-021-00824-3.","DOI":"10.1007\/s11523-021-00824-3"},{"key":"3781_CR37","doi-asserted-by":"crossref","unstructured":"Abu-Sbeih H et al. Outcomes of Vedolizumab therapy in patients with immune checkpoint Inh ibitor-induced colitis: a multi-center study. J Immunother Cancer, 6, 1, p. 142, doi: 10.1186\/s40425-018-0461-4.","DOI":"10.1186\/s40425-018-0461-4"},{"key":"3781_CR38","doi-asserted-by":"publisher","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives, (in eng), Cell Mol Immunol, vol. 21, no. 12, pp. 1354\u20131375, Dec 2024, https:\/\/doi.org\/10.1038\/s41423-024-01226-x","DOI":"10.1038\/s41423-024-01226-x"},{"key":"3781_CR39","doi-asserted-by":"publisher","unstructured":"Du F et al. Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors, (in eng), Biomark Res, vol. 13, no. 1, p. 35, Feb 26 2025, https:\/\/doi.org\/10.1186\/s40364-025-00748-4","DOI":"10.1186\/s40364-025-00748-4"},{"key":"3781_CR40","doi-asserted-by":"publisher","unstructured":"Tawbi HA, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced Melanoma, (in eng). N Engl J Med. Jan 6 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","DOI":"10.1056\/NEJMoa2109970"},{"key":"3781_CR41","doi-asserted-by":"publisher","unstructured":"Long GV, et al. Overall survival and response with nivolumab and relatlimab in advanced Melanoma, (in eng). NEJM Evid. Apr 2023;2(4):EVIDoa2200239. https:\/\/doi.org\/10.1056\/EVIDoa2200239.","DOI":"10.1056\/EVIDoa2200239"},{"key":"3781_CR42","doi-asserted-by":"publisher","first-page":"1188277","DOI":"10.3389\/fimmu.2023.1188277","volume":"14","author":"M Zhao","year":"2023","unstructured":"Zhao M, Huang H, He F, Fu X. Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma, (in eng). Front Immunol. 2023;14:1188277. https:\/\/doi.org\/10.3389\/fimmu.2023.1188277.","journal-title":"Front Immunol"},{"key":"3781_CR43","doi-asserted-by":"publisher","unstructured":"Bi W et al. Genome-wide analyses reveal the contribution of somatic variants to the immune landscape of multiple cancer types, (in eng), PLoS Genet, vol. 20, no. 1, p. e1011134, Jan 2024, https:\/\/doi.org\/10.1371\/journal.pgen.1011134","DOI":"10.1371\/journal.pgen.1011134"},{"key":"3781_CR44","doi-asserted-by":"publisher","unstructured":"Niu Z, Jin R, Zhang Y, Li H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials, (in eng), Signal Transduct Target Ther, vol. 7, no. 1, p. 353, Oct 5 2022, https:\/\/doi.org\/10.1038\/s41392-022-01200-x","DOI":"10.1038\/s41392-022-01200-x"},{"key":"3781_CR45","doi-asserted-by":"publisher","unstructured":"Hupperetz C, Lah S, Kim H, Kim CH. CAR T Cell Immunotherapy Beyond Haematological Malignancy, (in eng), Immune Netw, vol. 22, no. 1, p. e6, Feb 2022, https:\/\/doi.org\/10.4110\/in.2022.22.e6","DOI":"10.4110\/in.2022.22.e6"},{"key":"3781_CR46","doi-asserted-by":"publisher","first-page":"750022","DOI":"10.3389\/fcell.2021.750022","volume":"9","author":"A Vuleti\u0107","year":"2021","unstructured":"Vuleti\u0107 A, Mirja\u010di\u0107 Martinovi\u0107 K, Ti\u0161ma Mileti\u0107 N, Zoidakis J, Castellvi-Bel S, \u010cavi\u0107 M. Cross-Talk between tumor cells undergoing epithelial to mesenchymal transition and natural killer cells in tumor microenvironment in colorectal Cancer, (in eng). Front Cell Dev Biol. 2021;9:750022. https:\/\/doi.org\/10.3389\/fcell.2021.750022.","journal-title":"Front Cell Dev Biol"},{"key":"3781_CR47","doi-asserted-by":"publisher","first-page":"1311658","DOI":"10.3389\/fimmu.2023.1311658","volume":"14","author":"S Iadonato","year":"2023","unstructured":"Iadonato S, et al. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly Immunogenic tumors, (in eng). Front Immunol. 2023;14:1311658. https:\/\/doi.org\/10.3389\/fimmu.2023.1311658.","journal-title":"Front Immunol"},{"key":"3781_CR48","doi-asserted-by":"publisher","unstructured":"Yadav R, Hakobyan N, Wang JC. Role of next generation immune checkpoint inhibitor (ICI) therapy in Philadelphia negative classic myeloproliferative neoplasm (MPN): review of the Literature, (in eng). Int J Mol Sci. Aug 7 2023;24(15). https:\/\/doi.org\/10.3390\/ijms241512502.","DOI":"10.3390\/ijms241512502"},{"key":"3781_CR49","doi-asserted-by":"publisher","unstructured":"Wilde L, Kasner M. Targeting CD47: many misses; hopeful for a hit, (in eng), Blood, vol. 145, no. 5, pp. 460\u2013462, Jan 30 2025, https:\/\/doi.org\/10.1182\/blood.2024027222","DOI":"10.1182\/blood.2024027222"},{"key":"3781_CR50","doi-asserted-by":"publisher","unstructured":"Wang J et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy, (in eng), Nat Med, vol. 25, no. 4, pp. 656\u2013666, Apr 2019, https:\/\/doi.org\/10.1038\/s41591-019-0374-x","DOI":"10.1038\/s41591-019-0374-x"},{"key":"3781_CR51","doi-asserted-by":"publisher","first-page":"837230","DOI":"10.3389\/fimmu.2022.837230","volume":"13","author":"C Sun","year":"2022","unstructured":"Sun C, Wang B, Hao S. Adenosine-A2A receptor pathway in cancer Immunotherapy, (in eng). Front Immunol. 2022;13:837230. https:\/\/doi.org\/10.3389\/fimmu.2022.837230.","journal-title":"Front Immunol"},{"issue":"4","key":"3781_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, et al. PD-1 Blockade with nivolumab in relapsed or refractory hodgkin\u2019s lymph Oma. N Engl J Med. 2015;372(4):311\u20139. \/1\/22\/.","journal-title":"N Engl J Med"},{"key":"3781_CR53","doi-asserted-by":"crossref","unstructured":"Herrera AF et al. Nivolumab\u2009+\u2009AVD in Advanced-Stage Classic Hodgkin\u2019s Lymphoma. N Engl J Med, 391, 15, pp. 1379\u201389, doi: 10.1056\/NEJMoa2405888.","DOI":"10.1056\/NEJMoa2405888"},{"key":"3781_CR54","doi-asserted-by":"publisher","unstructured":"Usmani SZ et al. Pembrolizumab plus Lenalidomide and dexamethasone for patients with tr eatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol, 6, no. 9, pp. e448-e458, 2019\/9\/\/, https:\/\/doi.org\/10.1016\/S2352-3026(19)30109-7","DOI":"10.1016\/S2352-3026(19)30109-7"},{"key":"3781_CR55","doi-asserted-by":"crossref","unstructured":"Kuruvilla J et al. Pembrolizumab versus Brentuximab Vedotin in relapsed or refractory Cla Ssical hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multic entre, randomised, open-label, phase 3 study. Lancet Oncol, 22, 4, pp. 512\u201324, doi: 10.1016\/S1470-2045(21)00005-X.","DOI":"10.1016\/S1470-2045(21)00005-X"},{"key":"3781_CR56","doi-asserted-by":"publisher","first-page":"1010279","DOI":"10.3389\/fendo.2022.1010279","volume":"13","author":"A Chera","year":"2022","unstructured":"Chera A, Stancu AL, Bucur O. Thyroid-related adverse events induced by immune checkpoint inhibitors, (in eng). Front Endocrinol (Lausanne). 2022;13:1010279. https:\/\/doi.org\/10.3389\/fendo.2022.1010279.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3781_CR57","doi-asserted-by":"publisher","unstructured":"Ozimski LL, Gremmelspacher D, Aceto N. A fatal affair: Circulating tumor cell relationships that shape metastasis, (in eng), iScience, vol. 24, no. 9, p. 103073, Sep 24 2021, https:\/\/doi.org\/10.1016\/j.isci.2021.103073","DOI":"10.1016\/j.isci.2021.103073"},{"key":"3781_CR58","doi-asserted-by":"publisher","unstructured":"Patelli G, et al. Liquid biopsy for prognosis and treatment in metastatic colorectal cancer: Circulating tumor cells vs Circulating tumor DNA, (in eng). Target Oncol. May 2021;16(3):309\u201324. https:\/\/doi.org\/10.1007\/s11523-021-00795-5.","DOI":"10.1007\/s11523-021-00795-5"},{"key":"3781_CR59","doi-asserted-by":"publisher","unstructured":"Ahern E, Solomon BJ, Hui R, Pavlakis N, O\u2019Byrne K, Hughes BGM. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time? (in eng). J Immunother Cancer. Jun 2021;9(6). https:\/\/doi.org\/10.1136\/jitc-2020-002248.","DOI":"10.1136\/jitc-2020-002248"},{"key":"3781_CR60","doi-asserted-by":"publisher","unstructured":"Bai X, et al. Ginsenoside Rk3 modulates gut microbiota and regulates immune response of group 3 innate lymphoid cells to against colorectal tumorigenesis, (in eng). J Pharm Anal. Feb 2024;14(2):259\u201375. https:\/\/doi.org\/10.1016\/j.jpha.2023.09.010.","DOI":"10.1016\/j.jpha.2023.09.010"},{"key":"3781_CR61","doi-asserted-by":"publisher","unstructured":"Wei Y et al. The challenge and opportunity of gut microbiota-targeted nanomedicine for colorectal cancer therapy, (in eng), Imeta, vol. 3, no. 4, p. e213, Aug 2024, https:\/\/doi.org\/10.1002\/imt2.213","DOI":"10.1002\/imt2.213"},{"key":"3781_CR62","doi-asserted-by":"publisher","first-page":"1200947","DOI":"10.3389\/fmed.2023.1200947","volume":"10","author":"CL Moyer","year":"2023","unstructured":"Moyer CL, Brown PH. Targeting nuclear hormone receptors for the prevention of breast cancer, (in eng). Front Med (Lausanne). 2023;10:1200947. https:\/\/doi.org\/10.3389\/fmed.2023.1200947.","journal-title":"Front Med (Lausanne)"},{"key":"3781_CR63","doi-asserted-by":"publisher","unstructured":"Marcheteau E et al. Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer, (in eng), Cancers (Basel), vol. 13, no. 16, Aug 12 2021, https:\/\/doi.org\/10.3390\/cancers13164059","DOI":"10.3390\/cancers13164059"},{"key":"3781_CR64","doi-asserted-by":"publisher","first-page":"1452303","DOI":"10.3389\/fimmu.2024.1452303","volume":"15","author":"R Zhang","year":"2024","unstructured":"Zhang R, Jiang Q, Zhuang Z, Zeng H, Li Y. A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus. (in eng) Front Immunol. 2024;15:1452303. https:\/\/doi.org\/10.3389\/fimmu.2024.1452303.","journal-title":"(in eng) Front Immunol"},{"key":"3781_CR65","doi-asserted-by":"publisher","first-page":"640369","DOI":"10.3389\/fimmu.2021.640369","volume":"12","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wang Y. Role of epigenetic regulation in plasticity of tumor immune Microenvironment, (in eng). Front Immunol. 2021;12:640369. https:\/\/doi.org\/10.3389\/fimmu.2021.640369.","journal-title":"Front Immunol"},{"issue":"1","key":"3781_CR66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1868-7083-6-20","volume":"6","author":"S Kar","year":"2014","unstructured":"Kar S, et al. Expression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer, (in eng). Clin Epigenetics. 2014;6(1):20. https:\/\/doi.org\/10.1186\/1868-7083-6-20.","journal-title":"Clin Epigenetics"},{"key":"3781_CR67","doi-asserted-by":"publisher","unstructured":"Kong D et al. Transplant oncology and anti-cancer immunosuppressants, (in eng), Front Immunol, vol. 15, p. 1520083, 2024, https:\/\/doi.org\/10.3389\/fimmu.2024.1520083","DOI":"10.3389\/fimmu.2024.1520083"},{"key":"3781_CR68","doi-asserted-by":"publisher","unstructured":"McDonald BR, et al. Personalized Circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer, (in eng). Sci Transl Med. Aug 7 2019;11(504). https:\/\/doi.org\/10.1126\/scitranslmed.aax7392.","DOI":"10.1126\/scitranslmed.aax7392"},{"key":"3781_CR69","doi-asserted-by":"publisher","unstructured":"Panet F, Papakonstantinou A, Borrell M, Vivancos J, Vivancos A, Oliveira M. Use of ctDNA in early breast cancer: analytical validity and clinical potential, (in eng), NPJ Breast Cancer, vol. 10, no. 1, p. 50, Jun 19 2024, https:\/\/doi.org\/10.1038\/s41523-024-00653-3","DOI":"10.1038\/s41523-024-00653-3"},{"key":"3781_CR70","doi-asserted-by":"publisher","unstructured":"Niu S et al. Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis, (in eng), BMC Cancer, vol. 25, no. 1, p. 115, Jan 22 2025, https:\/\/doi.org\/10.1186\/s12885-025-13526-0","DOI":"10.1186\/s12885-025-13526-0"},{"key":"3781_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trim.2013.09.001","volume":"29","author":"X Yu","year":"2013","unstructured":"Yu X, et al. Characteristics of V\u03b41(+) and V\u03b42(+) \u03b3\u03b4 T cell subsets in acute liver allograft rejection, (in eng). Transpl Immunol. 2013;29:1\u20134. https:\/\/doi.org\/10.1016\/j.trim.2013.09.001. 118\u2009\u2013\u200922, Dec.","journal-title":"Transpl Immunol"},{"key":"3781_CR72","doi-asserted-by":"publisher","unstructured":"Liu X et al. Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors, (in eng), EBioMedicine, vol. 109, p. 105427, Nov 2024, https:\/\/doi.org\/10.1016\/j.ebiom.2024.105427","DOI":"10.1016\/j.ebiom.2024.105427"},{"key":"3781_CR73","doi-asserted-by":"publisher","unstructured":"Wang Y, et al. Faecalibacterium prausnitzii-derived extracellular vesicles alleviate chronic colitis-related intestinal fibrosis by macrophage metabolic reprogramming, (in eng). Pharmacol Res. Aug 2024;206:107277. https:\/\/doi.org\/10.1016\/j.phrs.2024.107277.","DOI":"10.1016\/j.phrs.2024.107277"},{"key":"3781_CR74","doi-asserted-by":"publisher","unstructured":"Abdel-Raoof Fouda M, et al. Effect of gut microbiota changes on cytokines IL-10 and IL-17 levels in liver transplantation patients, (in eng). BMC Infect Dis. Jan 30 2025;25(1):140. https:\/\/doi.org\/10.1186\/s12879-025-10466-9.","DOI":"10.1186\/s12879-025-10466-9"},{"key":"3781_CR75","doi-asserted-by":"publisher","unstructured":"Braithwaite IE, et al. Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial, (in eng). J Allergy Clin Immunol. Sep 2021;148(3):783\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2021.02.042.","DOI":"10.1016\/j.jaci.2021.02.042"},{"key":"3781_CR76","doi-asserted-by":"publisher","unstructured":"Liu Q, et al. Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study, (in eng). J Transl Med. Aug 29 2024;22(1):803. https:\/\/doi.org\/10.1186\/s12967-024-05617-6.","DOI":"10.1186\/s12967-024-05617-6"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03781-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03781-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03781-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:02:42Z","timestamp":1761087762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03781-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3781"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03781-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1930"}}